Piramal Imaging and ASAN Medical Center announce Research and Development Collaboration Agreement
BERLIN and SEOUL, South Korea, Nov. 17, 2017 /PRNewswire-iReach/ -- Piramal Imaging SA and the ASAN Medical Center (AMC) announced today that the parties have recently entered a research and development collaboration agreement to develop innovative PET tracers in South Korea and to expand their lasting strategic partnership.
The parties plan to conduct clinical studies at AMC with the intent of gaining regulatory approval for commercialization of innovative PET tracers in South Korea. The new PET imaging agents are being developed for an earlier detection and better characterization of life-threatening diseases to address unmet medical needs. Both parties intend to jointly assign future commercial partners for the production, supply and marketing of the 18F-based tracers in South Korea.
"We are delighted to be broadening our long-term relationship with AMC," said Andrew Stephens, M.D., Ph.D., Chief Medical Officer of Piramal Imaging. "Our collaboration has already yielded joint scientific contributions in oncology and cardiovascular imaging and will be further strengthened with this strategic partnership covering neuroimaging tracers."
Professor Jae Seung Kim, MD, PhD, Chair of the Department of Nuclear Medicine at AMC, added: "We are looking forward to get access to Piramal's innovative new PET imaging compounds such as for tau, neuroinflammation and thrombus imaging for further clinical investigation and development. AMC has demonstrated the successful development of innovative PET tracers and has strong expertise to run development studies with the goal of bringing new products to the market."
The R&D collaboration agreement has been facilitated by AMC's consultant BGM Associates GmbH, a Berlin-based Strategy and Transactions Advisory Firm.
About Piramal Imaging SA
Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key field of modern medicine: www.piramal.com/imaging
About ASAN Medical Center
AMC is one of the leading hospitals in South Korea, with particular expertise in the field of nuclear medicine. ASAN has successfully developed radiotracers and gained regulatory approval in South Korea. For more information please visit http://eng.amc.seoul.kr/asan/lang/main.do
For More Information:
Investor Relations: Hitesh Dhaddha / Bhavna Sinyal | Piramal Enterprises Ltd.
Tel #: +91 22 3046 6444 / +91 22 3046 6570 | investor.relations@piramal.com
For Media Queries:
Dimple Kapur/ Riddhi Goradia | Corporate Communications | Piramal Enterprises Ltd.
Tel#: +91 22 3351 4269/ 4083 | Dimple.Kapur@piramal.com/riddhi.goradia@piramal.com
Media Contact: Nicole Fletcher, Piramal Imaging, +1 (857) 202-1122, nicole.fletcher@piramal.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Piramal Imaging SA
